Autopsy report · NCT00555048

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Low accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months after it had already started.
1 participant enrolled.
Results were posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Fred Hutchinson Cancer Center
Sponsor type: University, hospital or other
Conditions: Graft Versus Host Disease; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab; busulfan; cyclophosphamide; methotrexate; tacrolimus; allogeneic hematopoietic stem cell transplantation
Participants: 1
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.